Edition:
United States

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

64.47USD
4:00pm EDT
Change (% chg)

$0.08 (+0.12%)
Prev Close
$64.39
Open
$64.54
Day's High
$65.44
Day's Low
$64.07
Volume
194,602
Avg. Vol
434,071
52-wk High
$75.13
52-wk Low
$32.40

Latest Key Developments (Source: Significant Developments)

Seattle Genetics in licensing deal with Immunomedics
Friday, 10 Feb 2017 07:24am EST 

Seattle Genetics Inc : Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors . Seattle Genetics Inc - planned bla for triple negative breast cancer indication; other solid tumors being explored in clinic . Seattle Genetics Inc - seattle genetics to lead development, manufacturing and commercialization of sacituzumab govitecan globally . Seattle Genetics inc says seattle genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics -upon closing of transactions contemplated by development, license agreement, immunomedics would receive an upfront payment of $250 million . Seattle Genetics Inc - granted right to purchase an additional 8,655,804 shares of common stock at a price of $4.90 per share . Seattle Genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics - would pay development, regulatory,sales-dependent milestone payments across multiple indications of up to total maximum of about $1.7 billion . Seattle Genetics Inc - 2017 guidance provided on february 9, does not take into account impact of transactions with immunomedics.  Full Article

Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint
Monday, 1 Aug 2016 06:59am EDT 

Seattle Genetics Inc : Takeda and Seattle Genetics announce positive data from phase 3 Alcanza clinical trial of ADCETRIS® (Brentuximab Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma . Randomized phase 3 clinical trial with ADCETRIS met primary endpoint . Intend to submit a supplemental biologics license application to FDA in first half of 2017 for approval .Phase 3 trial with ADCETRIS demonstrated highly statistically significant improvement in rate of objective response lasting at least 4 months.  Full Article

Seattle Genetics reports Q2 financial results
Tuesday, 26 Jul 2016 04:02pm EDT 

Seattle Genetics Inc : Sees intiating phase 2 trial of denintuzumab mafodotin (SGN-CD19a; 19A) in frontline diffuse large B-cell lymphoma during 2016. . Seattle Genetics reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S .Q2 revenue $95.4 million versus I/B/E/S view $94.1 million.  Full Article

Seattle Genetics, Inc initiates phase 1/2 trial of vadastuximab talirine
Monday, 22 Feb 2016 08:00am EST 

Seattle Genetics, Inc:Initiates phase 1/2 trial of vadastuximab talirine combination therapy for patients with untreated myelodysplastic syndrome.  Full Article

Seattle Genetics, Inc announces proposed public offering of common stock
Wednesday, 9 Sep 2015 04:01pm EDT 

Seattle Genetics, Inc:Announces proposed public offering of common stock.Says has commenced an underwritten public offering of $400 million of shares of its common stock.Says net proceeds from the offering to fund the ongoing commercialization of adcetris in the United States and Canada.  Full Article

Seattle Genetics initiates clinical trial of adcetris
Thursday, 9 Jul 2015 09:00am EDT 

Seattle Genetics:Says the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus).Lupus is a chronic autoimmune disease in which the body's own immune system overreacts and attacks healthy organs, causing inflammation, pain, permanent organ damage or death.ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on activated lymphocytes that are thought to play a key role in the development of autoimmune diseases, including lupus.Trial is designed to assess the safety and activity of ADCETRIS in adult patients with lupus. ADCETRIS is currently not approved for the treatment of lupus.  Full Article

Seattle Genetics and Unum Therapeutics enter into strategic cancer immunotherapy collaboration
Monday, 8 Jun 2015 09:00am EDT 

Seattle Genetics Inc and Unum Therapeutics:Says two companies have entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer.Under the terms of the agreement, Seattle Genetics will make an upfront payment of $25 mln and an equity investment of $5 mln in Unum's next round of private financing.The companies will initially develop two ACTR products incorporating Seattle Genetics' antibodies, and Seattle Genetics has an option to expand the collaboration to include a third ACTR product.Seattle Genetics and Unum will co-commercialize and share profits 50/50 on any co-developed programs in the United States.Seattle Genetics will retain exclusive commercial rights outside of the United States, paying Unum high single to mid-double digit royalties on ex-U.S. sales.Potential option fee and progress-dependent milestone payments to Unum under the collaboration may total up to $615 million across all three ACTR programs.  Full Article

More From Around the Web

Photo

Seattle Genetics to resume trials as FDA lifts clinical hold

Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug.